









Markets
/
Stocks
/
nasdaq-abbv
/

AbbVie Inc

ABBV

207.111USD

+2.181+1.06%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

327.37BMarket Cap

87.52P/E TTM



AbbVie Inc

207.111

+2.181+1.06%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of AbbVie Inc

Currency: USD Updated: 2026-03-24

Key Insights

AbbVie Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 251.44.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AbbVie Inc's Score

Industry at a Glance

Industry Ranking

40 / 157

Overall Ranking

125 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

AbbVie Inc Highlights

StrengthsRisks

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 263.76%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 263.76%.

Overvalued

The company’s latest PE is 86.72, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.33B shares, increasing 0.10% quarter-over-quarter.

Held by Manning & Napier Group, LLC

Star Investor Manning & Napier Group, LLC holds 356.00 shares of this stock.

Analyst Rating

Based on 33 analysts

Buy

Current Rating

251.444

Target Price

+22.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of AbbVie Inc is 8.73, ranking 24 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 16.62B, representing a year-over-year increase of 10.04%, while its net profit experienced a year-over-year increase of 5743.75%.

Score

Industry at a Glance

Previous score

8.73

Change



Financials

5.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.51

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

AbbVie Inc's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of AbbVie Inc is 5.05, ranking 151 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 86.72, which is 105.28% below the recent high of 178.02 and 74.93% above the recent low of 21.74.

Score

Industry at a Glance

Previous score

5.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 40/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of AbbVie Inc is 7.70, ranking 98 out of 157 in the Pharmaceuticals industry. The average price target is 245.00, with a high of 289.00 and a low of 187.64.

Score

Industry at a Glance

Previous score

7.64

Change

0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 33 analysts

Buy

Current Rating

251.444

Target Price

+22.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

AbbVie Inc

ABBV

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of AbbVie Inc is 6.76, ranking 61 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 227.61 and the support level at 192.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.67

Change

0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-5.462

Sell

RSI(14)

28.253

Sell

STOCH(KDJ)(9,3,3)

9.788

Oversold

ATR(14)

6.036

Low Volatility

CCI(14)

-111.621

Sell

Williams %R

89.697

Oversold

TRIX(12,20)

-0.292

Sell

StochRSI(14)

22.849

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

205.954

Buy

MA10

214.371

Sell

MA20

222.431

Sell

MA50

222.438

Sell

MA100

224.359

Sell

MA200

215.426

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of AbbVie Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 74.86%, representing a quarter-over-quarter decrease of 0.13%. The largest institutional shareholder is The Vanguard, holding a total of 179.94M shares, representing 10.18% of shares outstanding, with 3.82% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

176.93M

+0.24%

BlackRock Institutional Trust Company, N.A.

92.78M

+0.74%

State Street Investment Management (US)

79.82M

-0.25%

Geode Capital Management, L.L.C.

40.44M

+3.22%

JP Morgan Asset Management

36.42M

-2.81%

Norges Bank Investment Management (NBIM)

23.10M

-7.94%

Capital Research Global Investors

25.23M

-0.14%

Charles Schwab Investment Management, Inc.

25.96M

-3.08%

Fidelity Management & Research Company LLC

19.95M

+1.53%

Morgan Stanley Smith Barney LLC

23.97M

+1.96%

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AbbVie Inc is 9.20, ranking 13 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.40. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.